BRPI1012811A2 - vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune - Google Patents

vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune

Info

Publication number
BRPI1012811A2
BRPI1012811A2 BRPI1012811A BRPI1012811A BRPI1012811A2 BR PI1012811 A2 BRPI1012811 A2 BR PI1012811A2 BR PI1012811 A BRPI1012811 A BR PI1012811A BR PI1012811 A BRPI1012811 A BR PI1012811A BR PI1012811 A2 BRPI1012811 A2 BR PI1012811A2
Authority
BR
Brazil
Prior art keywords
vaccines
compositions
obtaining
methods
immune response
Prior art date
Application number
BRPI1012811A
Other languages
English (en)
Inventor
Deborah Long
Jessica Flechtner
Mojca Skoberne
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Publication of BRPI1012811A2 publication Critical patent/BRPI1012811A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
BRPI1012811A 2009-05-22 2010-05-24 vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune BRPI1012811A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18078409P 2009-05-22 2009-05-22
US23562809P 2009-08-20 2009-08-20
US24058709P 2009-09-08 2009-09-08
US24062609P 2009-09-08 2009-09-08
US30591810P 2010-02-18 2010-02-18
PCT/US2010/035998 WO2010135747A1 (en) 2009-05-22 2010-05-24 Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Publications (1)

Publication Number Publication Date
BRPI1012811A2 true BRPI1012811A2 (pt) 2016-03-29

Family

ID=43126545

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012811A BRPI1012811A2 (pt) 2009-05-22 2010-05-24 vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune

Country Status (17)

Country Link
US (3) US8617564B2 (pt)
EP (3) EP2432504B1 (pt)
JP (2) JP5771605B2 (pt)
KR (1) KR101746872B1 (pt)
CN (2) CN102458463B (pt)
AU (1) AU2010249330B2 (pt)
BR (1) BRPI1012811A2 (pt)
CA (1) CA2797937C (pt)
ES (1) ES2732815T3 (pt)
IL (1) IL216508A (pt)
MX (1) MX2011012347A (pt)
MY (1) MY159500A (pt)
NZ (1) NZ597182A (pt)
RU (1) RU2585961C9 (pt)
SG (1) SG176207A1 (pt)
WO (2) WO2010135747A1 (pt)
ZA (1) ZA201109444B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
US20130039947A1 (en) 2010-03-12 2013-02-14 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
WO2012074881A2 (en) * 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
WO2012139099A2 (en) * 2011-04-08 2012-10-11 Duke University Herpes simplex virus vaccine
US9624273B2 (en) * 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
US20140093537A1 (en) * 2012-09-30 2014-04-03 Nanobio Corporation Immunogenic compositions comprising nanoemulsion and methods of administering the same
CN103074337B (zh) * 2012-12-04 2014-07-09 昆明寰基生物芯片产业有限公司 一段单纯疱疹病毒dna序列及应用
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
WO2015134368A2 (en) 2014-03-03 2015-09-11 Albert Einstein College Of Medicine Of Yeshiva University Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
PT3411388T (pt) 2016-02-01 2021-12-20 Simplexia Ab Glicoproteína g truncada do vírus herpes simplex 2
EP3519427A4 (en) * 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
KR101962683B1 (ko) * 2016-09-28 2019-03-27 주식회사 에스엘백시젠 Hsv-2 감염 예방 및 치료용 dna 백신
EP3615060A4 (en) 2017-04-26 2021-06-09 Merck Sharp & Dohme Corp. HSV ANTIGENIC PEPTIDES AND HSV PROTEIN VACCINES
US11213582B2 (en) * 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
EP3849587A4 (en) 2018-09-12 2022-06-29 Affinivax, Inc. Multivalent pneumococcal vaccines
AU2020240135A1 (en) 2019-03-21 2021-10-14 Lonza Sales Ag Extracellular vesicles for vaccine delivery
WO2020191377A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
CN109943592B (zh) * 2019-04-29 2020-11-17 华中农业大学 含猪伪狂犬病病毒gD蛋白基因的重组杆状病毒转移载体、重组杆状病毒及制备方法和应用
CN110845583A (zh) * 2019-11-18 2020-02-28 维塔恩(广州)医药有限公司 水痘带状疱疹病毒相关抗原短肽及其应用
CN110746497A (zh) * 2019-11-18 2020-02-04 维塔恩(广州)医药有限公司 肺炎衣原体相关抗原短肽及其应用
CN110804088A (zh) * 2019-11-18 2020-02-18 维塔恩(广州)医药有限公司 巨细胞病毒相关抗原短肽及其应用
CN110724181A (zh) * 2019-11-18 2020-01-24 维塔恩(广州)医药有限公司 单纯疱疹病毒相关抗原短肽及其应用

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) * 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US7264817B1 (en) * 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5612041A (en) * 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
EP0471778A1 (en) * 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
DE69131200T2 (de) * 1990-08-02 1999-12-09 Chiron Corp Herpes simplex virus vp16 impfstoffe
DK31991D0 (da) * 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1994029456A2 (en) 1993-06-08 1994-12-22 Abbott Laboratories Herpes simplex virus type-2 protease
EP0714399A4 (en) 1993-08-20 1999-01-27 Smithkline Beecham Corp HSV-2 UL26 GEN, ENVELOPE PROTEINS, IMMUNOASSAYS AND PROTEAS INHIBITORS
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US7094767B2 (en) * 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US5807557A (en) 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
US6156319A (en) * 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1996032962A1 (en) * 1995-04-21 1996-10-24 The University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
US5958895A (en) * 1996-10-23 1999-09-28 American Home Products Corporation DNA vaccines for herpes simplex virus
CN1324139C (zh) * 1996-10-23 2007-07-04 惠氏 疫苗
JP2001508649A (ja) 1996-11-04 2001-07-03 スミスクライン・ビーチャム・コーポレイション ２型単純ヘルペスウイルス由来の新規コーディング配列
US6218103B1 (en) * 1997-04-16 2001-04-17 Arch Development Corporation Herpes simplex virus US3 and ICP4 as inhibitors of apoptosis
JP2002503251A (ja) 1997-06-02 2002-01-29 カイロン コーポレイション 単純ヘルペスウイルスｖｐ２２ワクチンおよび使用の方法
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) * 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
ES2273482T3 (es) * 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. Composiciones de vacunas combinadas.
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
NZ509974A (en) * 1998-08-07 2003-10-31 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
JP2003502345A (ja) * 1999-06-10 2003-01-21 メリアル ペットまたはスポ−ツ用動物のためのｄｎａワクチン
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
CN1376201A (zh) * 1999-09-30 2002-10-23 华盛顿大学 免疫学上重要的单纯疱疹病毒抗原
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
JP2003517042A (ja) 1999-12-17 2003-05-20 アメリカン・サイアナミド・カンパニー 単純ヘルペスウイルスワクチンに対する免疫応答を強化する方法
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
NZ522734A (en) 2000-06-29 2005-05-27 Corixa Corp Compositions and methods for the diagnosis and treatment of herpes simplex virus infection using immunogneic portions of an HSV antigen
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US7569218B2 (en) * 2000-07-27 2009-08-04 The Trustees Of The University Of Pennsylvania Compositions for and methods of using herpes simplex virus glycoprotein D to suppress immune responses
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
WO2003034981A2 (en) * 2000-11-16 2003-05-01 University Of Maryland, Baltimore Prevention of recurrent viral disease
US6867000B2 (en) * 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
WO2004030608A2 (en) 2001-06-05 2004-04-15 The Regents Of The University Of Michigan Nanoemulsion vaccines
JP4519461B2 (ja) * 2001-07-31 2010-08-04 ユニヴァーシティ オブ ワシントン 免疫学的に重要な単純ヘルペスウイルス抗原およびそれを用いる方法
AU2002323443A1 (en) 2001-09-04 2003-03-18 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030219448A1 (en) 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
US20080299140A1 (en) * 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
EP2263686B1 (en) * 2002-07-18 2012-12-26 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
US7267940B2 (en) * 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
EP1670507A4 (en) * 2003-09-12 2007-10-17 Antigenics Inc VACCINE FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY HERPES SIMPLEX VIRUS
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
JP5492418B2 (ja) * 2005-11-18 2014-05-14 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
WO2007106404A2 (en) 2006-03-10 2007-09-20 The Regents Of The University Of California Vaccine for viruses that cause persistent or latent infections
AU2007275047A1 (en) 2006-07-20 2008-01-24 University Of Washington Compositions and methods for vaccinating against HSV-2
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
EP2059255A4 (en) * 2006-09-08 2011-08-31 Univ Pennsylvania VACCINES AGAINST HSV-1 AND HSV-2 AND METHODS OF USE
EP2087128A4 (en) 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
US8057804B2 (en) * 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
EP2526966B1 (en) * 2006-12-28 2016-03-23 The Trustees of The University of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US7785605B2 (en) 2007-07-05 2010-08-31 University Of Kansas Herpes simplex virus mutant ICP0 protein
WO2009006680A1 (en) 2007-07-06 2009-01-15 Sydney West Area Health Service Epitopes of herpes simplex virus
EP2293814A4 (en) * 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION ADJUVANTS
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
AU2009266924B2 (en) 2008-07-01 2015-12-10 Genocea Biosciences, Inc. Antigen screening system
CA2781805A1 (en) 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US20120100171A1 (en) 2009-03-09 2012-04-26 William Henry Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
US9089537B2 (en) 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
US20130195961A1 (en) 2010-03-09 2013-08-01 Kejian Yang Novel mucosal vaccination approach for herpes simplex virus type-2
JP2013545448A (ja) 2010-10-20 2013-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド クラミジア抗原及びその使用
WO2012074881A2 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9624273B2 (en) 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES

Also Published As

Publication number Publication date
AU2010249330A1 (en) 2012-01-19
EP3756684A1 (en) 2020-12-30
EP2432504A4 (en) 2013-07-31
MY159500A (en) 2017-01-13
EP3590533A1 (en) 2020-01-08
EP2432504B1 (en) 2019-05-01
JP2012527486A (ja) 2012-11-08
CN106924728B (zh) 2021-02-05
JP6096839B2 (ja) 2017-03-15
CN102458463A (zh) 2012-05-16
US20100330112A1 (en) 2010-12-30
MX2011012347A (es) 2012-02-21
NZ597182A (en) 2014-07-25
RU2011147153A (ru) 2013-06-27
US8617564B2 (en) 2013-12-31
RU2585961C9 (ru) 2016-12-27
KR20120087805A (ko) 2012-08-07
AU2010249330B2 (en) 2015-11-05
US10653771B2 (en) 2020-05-19
JP5771605B2 (ja) 2015-09-02
WO2010135749A1 (en) 2010-11-25
WO2010135749A9 (en) 2011-07-21
RU2585961C2 (ru) 2016-06-10
KR101746872B1 (ko) 2017-06-14
CN102458463B (zh) 2017-01-18
ES2732815T3 (es) 2019-11-26
SG176207A1 (en) 2011-12-29
ZA201109444B (en) 2016-09-28
CA2797937C (en) 2020-01-14
CN106924728A (zh) 2017-07-07
WO2010135747A1 (en) 2010-11-25
EP2432504A1 (en) 2012-03-28
IL216508A (en) 2016-08-31
US20140227307A1 (en) 2014-08-14
US9895436B2 (en) 2018-02-20
CA2797937A1 (en) 2010-11-25
US20180369365A1 (en) 2018-12-27
JP2015178529A (ja) 2015-10-08
IL216508A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
BRPI1012811A2 (pt) vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune
HRP20181343T1 (hr) Postupci i pripravci za induciranje imunosnog odgovora na egfrviii
BRPI1012635A2 (pt) "métodos e composições para imunização contra o vírus"
EP2023952A4 (en) INDUCTION OF IMMUNE REACTIONS TO THE INFLUENZA AVIRUSES USING POLYPEPITD AND NUCLEIC ACID COMPOSITIONS
BRPI0920283A2 (pt) composição e método para induzir resposta imunológica humoral
BRPI0920282A2 (pt) composição e método para induzir resposta imunológica humoral
BR112012019757A2 (pt) composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular
BRPI0908348A2 (pt) Métodos e kits de composições para acentuar a resposta imunológica a uma condição respiratória
IL261562A (en) Preparations containing decitabine derivatives and their uses
ZA201307394B (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2069376A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS
DK3170508T3 (da) Vaccineformuleringer
BR112013032675A2 (pt) composição adjuvante de vacina compreendendo partículas de inulina
EP2598120A4 (en) COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
BR112014005404A2 (pt) citomegalovírus (cmv) defectivo em replicação condicional, composição, métodos para induzir uma resposta imune contra cmv e para preparo de cmv defectivo em replicação condicional, e, uso do cmv defectivo em replicação condicional
BRPI1011902A2 (pt) composições e métodos para potencialização de respostas imunes antígeno-específicas
BRPI1006863A2 (pt) composições de vacina e plasmodium purificado
BRPI1007721A2 (pt) composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduo
DK2909334T3 (da) Gensignaturer af inflammatoriske lidelser, som er relateret til leveren og Crohns sygdom
BR112013016503A2 (pt) composições e método de vacina de vírus da diarreia viral bovina tipo 1b.
HK1175807A1 (zh) 單純疱疹病毒疫苗
EP2643014A4 (en) HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
EP2484378A4 (en) VACCINE COMPOSITION AGAINST HEPATITIS C VIRUS
ZA201003964B (en) Compositions for and methods of enhancing the immune response to antigens
EP2484376A4 (en) METHOD, KIT, PLASMID AND COMPOSITION FOR INDUCING AN IMMUNE RESPONSE AGAINST THE DENGUE VIRUS USING DNA VACCINES AND CHIMERIC VIRUSES

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2724 DE 21/03/2023.